

CUMULATIVE INDEX 1997

Volume 24

March	INFECTIONS IN PERINATOLOGY, pages 1-290
June	PERINATAL CARE FOR CHRONIC MATERNAL CONDITIONS, pages 291-529
September	NEUROLOGIC DISORDERS IN THE NEWBORN, PART I: CEREBROVASCULAR DISEASE, pages 531-733
December	NEUROLOGIC DISORDERS IN THE NEWBORN, PART II, pages 735-906

Note: Page numbers of article titles are in **boldface** type

- Abortion, recurrent, in antiphospholipid syndrome, 300-302
risk of, after fertility treatments, 322-323
in radiation therapy, 375
in systemic lupus erythematosus, 295-296
spontaneous, in sexually transmitted disease, 24-25
- N-Acetylaspartate metabolism, magnetic resonance spectroscopy of, 704-705
- N-Acetyl-aspartyl-glutamate, magnetic resonance spectroscopy of, 705
- Acetylcholine receptor antibodies, in neonatal myasthenia, 831
- Acid maltase deficiency, cardiac and neurologic manifestations of, 818
myopathies in, 839-840
- Acid-base status, versus mean oxygen saturation, at birth, 558
- Acidemias, organic, encephalopathy in, 780-781
- Acidosis, in asphyxia, 608
lactic, encephalopathy in, 782-783
- Acquired immunodeficiency infection. *See Human immunodeficiency virus infection.*
- Activity, in pregnancy, restriction of, in hypertension, 401
versus caloric cost, 435-436
- Acyclovir, in herpes simplex virus infections, in neonates, 272-275, 791
in pregnancy, 142-144, 269-271
in varicella zoster virus infections, 195, 277-278, 794
- Acylcarnitine measurement, in inborn errors of metabolism, 776
- Acy-CoA dehydrogenases, deficiencies of, in encephalopathy in, 781-782, 817-818
- Adenosine, in hypoxic-ischemic brain injury prevention, 637
- Adenoviral infections, of central nervous system, 796
- β -Adrenergic blocking agents, in hypertension, in pregnancy, 398-399
in Marfan syndrome, in pregnancy, 458
- Age factors, in pregnancy, 335-338
- AIDS. *See Human immunodeficiency virus infection.*
- Allergy. *See also Asthma.*
pregnancy in, 407-432
angioedema, 423-427
atopic dermatitis, 427-429
immunoglobulin E in, 407-408
rhinitis, 419-423
treatment of, 408-409
urticaria, 423-427
- Allopurinol, in hypoxic-ischemic brain injury prevention, 642-643
- Amikacin, in neonates, 254-255
- Amino acid(s), measurement of, in inborn errors of metabolism, 776-777
metabolism of, disorders of, encephalopathy in, 777-780
magnetic resonance spectroscopy in, 704-706
- 1-Amino-3,5-dimethyladamantine hydrochloride, in hypoxic-ischemic brain injury prevention, 638-639

- Aminoglycosides, in neonates, 254–255
 Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor, in hypoxic-ischemic brain injury, 629
 antagonists to, 639
 Aminophylline, cerebral blood flow effects of, 538
 21-Aminosteroids, in hypoxic-ischemic brain injury prevention, 642
 Ammonia accumulation, in inborn errors of metabolism, 776–778
 Amniotic fluid, infections of. *See Intra-amniotic infections.*
 Ampicillin, in neonates, 261
 Anal sphincter injury, in labor and delivery, 357–358
 Anemia, in kidney disease, in pregnancy, 488
 Anencephaly, brain death determination in, 875, 877–878
 Anesthesia, local, inadvertent fetal injection of, seizures in, 763
 Angloedema, pregnancy in, 423–427
 Angiography, digital subtraction, of brain, 874–875
 Angiotensin-converting enzyme inhibitors, in hypertension, in pregnancy, 400
 Anterior horn cell disorders, 828–829
 Antibiotics, 251–266
 in breast milk, 252–253
 in group B streptococcal infections, 64–65
 prophylactic, 65–68
 in intra-amniotic infections, 47
 in neonates, aminoglycosides, 254–255
 aztreonam, 255
 carbapenems, 259
 cephalosporins, 258–259
 chloramphenicol, 259–260
 dosages for, 254, 256–257
 macrolides, 260
 metronidazole, 260–261
 penicillins, 261–262
 pharmacology of, 253–254
 vancomycin, 262–263
 in pregnancy, 251–252
 in premature rupture of membranes, 51–52
 in *Ureaplasma urealyticum* infections, in neonates, 98
 in pregnancy, 93–94
 Antibodies, in antiphospholipid syndrome, 302–304
 in systemic lupus erythematosus, neonatal lupus from, 297
 maternal-child transfer of, 507–509
 Anticardiolipin antibodies, in antiphospholipid syndrome, 302–304
 Anticoagulant, lupus, in antiphospholipid syndrome, 302–304
 Anticonvulsant agents, in hypoxic-ischemic brain injury prevention, 619–620, 636
 Antiepileptic drugs, in neonates, 766–767
 Antihistamines, in allergic reactions, in pregnancy, 426
 in rhinitis, in pregnancy, 421–422
 Antihypertensive agents, in pregnancy, 397–400, 402–403
 Antiphospholipid syndrome, pregnancy in, 300–310
 antibody testing in, 303–305
 complications of, 300–303
 diagnostic criteria for, 300
 loss of, 300–302
 obstetric management in, 307–310
 pathogenesis of, 305–307
 Antisera, in septic shock, 222
 Aortic disease, pregnancy in, 472–473
 Aortic valve disease, pregnancy in, 471
 Apnea testing, in brain death, 866–867
 Apoptosis, of neurons, in hypoxic-ischemic brain injury, 633
 Argininuria, deficiency, encephalopathy in, 777–778
 L-Arginine analogues, in hypoxic-ischemic brain injury prevention, 641
 Arginosuccinic acid lyase deficiency, encephalopathy in, 777–778
 Arginosuccinic acid synthetase deficiency, encephalopathy in, 777–778
 Arthrogryposis multiplex congenita, 841–842
 Asherman syndrome, pregnancy in, 334–335
 Asphyxia, causes of, 754
 cerebral blood flow after, 536–537
 cerebral blood flow-energy metabolism relationships in, 534
 cerebral energy metabolism after, 536–537
 cerebral palsy from, 609–611
 definition of, 607–608
 diagnosis of, 755–756
 hypoxic-ischemic brain injury in. *See Hypoxic-ischemic brain injury.*
 mortality in, 608
 seizures in, 754–756
 Aspirin, in antiphospholipid syndrome, 307–310
 in pre-eclampsia prevention, 403
 Assisted reproductive technologies, in Turner syndrome, 461
 multifetal reduction in, 331–332
 multiple gestations in, 323–332
 oocyte donation in, 335–338
 pregnancy outcome in, 329
 Asthma, pregnancy in, 409–419
 definition of, 409–410
 diagnosis of, 414, 416–417

- obstetric management in, 419
pathophysiology of, 410
pregnancy affected by, 412–414
pregnancy effects on disease, 411–412
symptoms and signs of, 409–410
treatment of, 414–415, 418
triggering factors for, 411
- Atopic dermatitis, pregnancy in, 427–429
- Atrial septal defect, pregnancy in, 469–471
- Auditory evoked potentials, in extracorporeal membrane oxygenation, 659
- Auditory functional assessment, in brain death determination, 865
- Autoantibodies, in antiphospholipid syndrome, 302–304
in systemic lupus erythematosus, neonatal lupus from, 297
- Autoimmune diseases, neonatal, myasthenia gravis, 831
pregnancy in, antiphospholipid syndrome, 300–310
systemic lupus erythematosus, 292–299, 490–491
thrombocytopenia, 302
- Autoregulation, of cerebral blood flow, blood pressure and, 534–535
perfusion pressure and, 532–533
- Avoidance therapy, for allergy, 408–409, 414
- Axonal neuropathy, 830
- Azithromycin, in neonates, 260
- Azlocillin, in neonates, 262
- Aztreonam, in neonates, 255
- B lymphocytes, function of, in neonates, 242
in fetal and neonatal defense system, 513, 515–516
- Bacillus Calmette-Guerin vaccination, in tuberculosis, 118–119, 236
- Bacteria, maternal-placental-fetal interactions with. *See Infections, maternal-placental-fetal interactions in.*
- Bacterial sepsis. *See Sepsis, neonatal.*
- Bacterial vaginosis, diagnosis of, 93
preterm birth and, 33–36
- Bacteriuria, in pregnancy, 348–349
- Barth syndrome, cardiac and neurologic manifestations of, 818
- Basal ganglia, disorders of, in metabolic disorders, magnetic resonance imaging of, 709
hypermyelination of, in hypoxic-ischemic brain injury, 612
- Beer-Lambert law, in near-infrared spectroscopy, 549
- Benign infantile myopathy, 840
- Benign neonatal sleep myoclonus, versus seizures, 737
- Benzodiazepines, in hypoxic-ischemic brain injury prevention, 640
in seizures, 766
- Beta blockers, in hypertension, in pregnancy, 398–399
in Marfan syndrome, in pregnancy, 458
- Bicuspid aortic valve, pregnancy in, 471–472
- Bilirubin excess, brain injury in, magnetic resonance spectroscopy of, 710–711
- Biopsy, cervical, in pregnancy, 371–373
- Birth trauma, 845–857
brachial plexus, 850–852
brain death in, 863
cranial, 846–848
cranial nerve, 848–849
incidence of, 845
phrenic nerve, 850
risk factors for, 845
scalp, 846–847
spinal cord, 849–850
- Bladder, changes of, in pregnancy, 344
fistulas of, in labor and delivery, 356
- Infections of, in pregnancy, 348
- Intrapartum injury of, 355–357
- neck mobility of, after pregnancy, 361
- neurogenic, pregnancy in, 360
- surgery on, pregnancy after, 359
- Blood flow, cerebral. *See Cerebral blood flow.*
- uterine, fetal hypoxia and, 554–555
- Blood pressure, abnormal, cerebral blood flow in, 534–535
- intraventricular hemorrhage in, 590–591
- control of, in hypoxic-ischemic brain injury, 618–619
- measurement of, in pregnancy, 392–393
- of children, versus maternal nutrition, 442
- systolic, in extracorporeal membrane oxygenation, versus sequelae, 665
- Blood-oxygenation-level-dependent (BOLD) contrast method, in magnetic resonance imaging, 697
- Botulism, infantile, 832–833
- Brachial plexus injury, in cardiac surgery, 815
in labor and delivery, 850–852
- Brain, blood flow in. *See Cerebral blood flow.*
- dysgenesis of, in cardiac disease, 816
- injury of. *See also Neurologic disorders.*
hypoxic-ischemic. *See Hypoxic-ischemic brain injury.*
- in extracorporeal membrane oxygenation. *See Extracorporeal membrane oxygenation.*
- in premature infants, 567–587
- in hydrocephalus, 600–602

- Brain (Continued)**
- in periventricular hemorrhagic infarction, 568-574
 - in periventricular leukomalacia, 574-582
 - neuropathology of, 567-568
 - malformations of, seizures in, 759-760
 - tumors of, in neurofibromatosis, 453-454
 - vulnerability of, to hypoxic-ischemic injury, 633-635
- Brain death, 859-882**
- causes of, 863-864
 - cerebral blood flow assessment in, 871-874
 - digital subtraction angiography in, 874
 - Doppler studies in, 873
 - radioisotopic methods in, 872-873
 - cerebral metabolic activity assessment in, 875-876
 - electroencephalography in, 869-871
 - epidemiology of, 861-862
 - guidelines for, 860-861
 - historical aspects of, 860-861
 - in anencephaly, 875, 877-879
 - neurodiagnostic evaluation in, 868-872
 - neurologic examination in, 863, 865-868
 - apnea testing in, 866-867
 - duration of, 867-868
- Brainstem, disorders of, hypoxic-ischemic, 611**
- in metabolic disorders, magnetic resonance imaging of, 709
 - normal anatomy of, ultrasonography of, 679
- Brainstem auditory evoked potentials, in extracorporeal membrane oxygenation, 659**
- Brainstem reflexes, evaluation of, in brain death, 863, 865**
- Brainstem release phenomena, 749**
- Branched-chain ketoacid dehydrogenase deficiency, in maple syrup urine disease, encephalopathy in, 778-779**
- Breastfeeding, antibiotic excretion in, 252-253**
- hepatitis B and, 184-185
 - HIV transmission in, 164-165
 - in neonatal infection prevention, 12
 - tuberculosis and, 116, 122
- Bronchoconstriction, in asthma, 410**
- Bronchodilators, in asthma, 414**
- Bronchopulmonary dysplasia, extracorporeal membrane oxygenation in, versus neurodevelopmental outcome, 668**
- Bypass, cardiopulmonary. See *Cardiopulmonary bypass; Extracorporeal membrane oxygenation.***
- C1 inhibitor, recombinant, in allergic reactions, in pregnancy, 426-427**
- Calcium, accumulation of, in hypoxic-ischemic brain injury, 630, 634**
- prevention of, 637-642
 - imbalance of, seizures in, 756
 - supplementation with, in pregnancy, 440
- Calcium channel blockers, in hypoxic-ischemic brain injury prevention, 640**
- Calculi, kidney, pregnancy in, 350**
- Caloric cost, of pregnancy, 435-436**
- Calpain antagonists, in hypoxic-ischemic brain injury prevention, 641**
- Canavan's disease, encephalopathy in, magnetic resonance imaging of, 710**
- Cancer, pregnancy in, cervical, 369-378**
- renal, 352
- Candidiasis, of central nervous system, 803-804**
- Carbamyl phosphate synthetase deficiency, encephalopathy in, 777-778**
- Carbenems, in neonates, 259**
- Carbon-13, in magnetic resonance spectroscopy, 699, 704-706**
- Carbon dioxide, partial pressure of, in apnea testing for brain death, 866-867**
- in cerebral blood flow regulation, 532
 - in extracorporeal membrane oxygenation, versus sequelae, 666
- Cardiopulmonary bypass, neurologic injury in, intraoperative, 809-812**
- postoperative, 812-815
- Cardiorespiratory failure, extracorporeal oxygenation in. See *Extracorporeal membrane oxygenation.***
- Cardiovascular disorders, congenital. See *Congenital cardiac disease.***
- in Marfan syndrome, 457-458
 - in Turner syndrome, 459
 - of adults, versus maternal nutrition, 442-443
- Carnitine, measurement of, in inborn errors of metabolism, 776**
- Carnitine:palmitoyltransferase II deficiency, encephalopathy in, 782, 817-818**
- myopathy in, 840-841
- Carotid artery, right common, ligation and reconstruction of, in extracorporeal membrane oxygenation, 559-662**
- Catalase, in hypoxic-ischemic brain injury prevention, 642**
- CATCH22 syndrome, cardiac and neurologic manifestations of, 817**
- CD40L deficiency, in neonates, 242-244**
- Cefepime, in neonates, 259**
- Cefotaxime, in neonates, 258**
- Ceftazidime, in neonates, 258**
- Central core disease, 837-838**

- Central nervous system.** *See also Brain.*
 anomalies of, with muscular dystrophies, 834–836
 infections of, 787–806
 adenoviruses, 796
 candidiasis, 803–804
 Citrobacter, 799
 cytomegalovirus, 788–789
 enteroviruses, 794–795
 herpes simplex virus, 132–133, 135, 789–791
 human immunodeficiency virus, 795–796
 listeriosis, 797–799
 lymphocytic choriomeningitis virus, 796
 Mycoplasma hominis, 801
 parvovirus B19, 796
 protozoan, 802–803
 rubella, 796
 seizures in, 757–759
 streptococcus group B, 797
 toxoplasmosis, 802
 varicella zoster virus, 792–794
 malformations of, seizures in, 759–760
 tumors of, in neurofibromatosis, 453–454
- Centronuclear/myotubular myopathy**, 838
- Cephalohematoma**, 847
- Cephalosporins**, in neonates, 258–259
- Cerebellum**, ultrasonography of, in
 hemorrhage, 680–681
 normal anatomy of, 679
- Cerebral blood flow**, 531–546
 assessment of, in brain death determination, 871–874
 energy metabolism and, 531, 534
 in extracorporeal membrane oxygenation, 659–662
 in fetus, during contractions, 552–555
 in premature infants, periventricular leukomalacia and, 580–581
 magnetic resonance imaging of, 697
 pathophysiology of, 534–538
 drug-induced, 537–538
 high blood pressure, 535
 hypoglycemia, 535–536
 intracranial hemorrhage, 537
 intraventricular hemorrhage, 590–596
 low blood pressure, 534–535
 periventricular leukomalacia, 580–581
 postasphyxiated state, 536–537
 seizures, 537
 regulation of, 531–534
 carbon dioxide in, 532
 energy metabolism and, 531
 neurogenic, 533–534
 oxygen in, 532
 perfusion pressure and, 532–533
 research methods for, 538–542
 cytochrome oxidase redox state, 541
- Kety-Schmidt, 538
 positron emission tomography, 539–540
 quantitative measurements in, 540–541
 radioactive isotopes in, 541–542
 single photon emission tomography, 539
 xenon-133 clearance, 538–539
- Cerebral blood volume**, measurement of, 540–541
- Cerebral energy metabolism**, after
 asphyxia, 536–537
 cerebral blood flow and, 531, 534
 failure of, in hypoxic-ischemic brain injury, 629, 634
 in asphyxia, 608
 magnetic resonance spectroscopy of, 703–706, 715–716
 maintenance of, in hypoxic-ischemic brain injury, 635
 measurement of, in brain death determination, 875
 near-infrared spectroscopy in. *See Near-infrared spectroscopy.*
 positron emission tomography in, 539–540
- Cerebral hemisphere**, right, injury of, in extracorporeal membrane oxygenation, 659–662
- Cerebral hemorrhage**, magnetic resonance imaging of, 711–712
- Cerebral palsy**, after extracorporeal membrane oxygenation, 662, 664–667
 birth trauma and, 848
 in hypoxic-ischemic brain injury, 609–611
- in premature infants**, clinical features of, 567–568
 in periventricular hemorrhagic infarction, 568–574
 in periventricular leukomalacia, 574–582
- Cerebral perfusion**, magnetic resonance imaging of, 697, 702–703
- Cerebral perfusion pressure**, diminished, hypoxic-ischemic brain injury in, 608, 628
 reperfusion injury inhibition in, 642–643
 in cerebral blood flow regulation, 532–533
 maintenance of, in hypoxic-ischemic brain injury, 619, 632–633
- Cerebral veins**, ultrasonography of, 683–685
- Cerebrospinal fluid analysis**, in herpes simplex virus infections, 140
- Cervical spine injury**, in labor and delivery, 849–850
- Cervix**, cancer of, pregnancy in, 369–378

- Cervix (*Continued*)
 biopsy in, 371-373
 conization in, 372-374
 delivery in, 377
 incidence of, 369
 invasive, 374
 prognosis for, 377
 screening for, 371-372
 staging of, 374-375
 treatment of, 375-376
 incompetent, pregnancy loss in, 334
 Cesarean section, genitourinary fistulas in,
 356
 Chagas disease, of central nervous system,
 803
 Chickenpox, 193-196, 277-278
 central nervous system disorders in,
 792-794
 Chlamydial infections, preterm birth and,
 33
 Chloramphenicol, in neonates, 259-260
 Chlorpheniramine, in allergic reactions, in
 pregnancy, 421, 426
 Cholesterol levels, of adults, versus
 maternal nutrition, 442-443
 Choline signal, in magnetic resonance
 spectroscopy, 704
 Choline-related compounds, in hypoxic-
 ischemic brain injury, 620
 Chorioamnionitis. *See Intra-amniotic
 infections.*
 Chromosomal syndromes, cardiac and
 neurologic manifestations of, 816-817
 Chronic lung disease, in neonates, 95-97
 Ciprofloxacin, in neonates, 263
 Circulatory arrest, deep hypothermic, in
 cardiac surgery, neurologic injury
 from, 807, 809-815
Citrobacter infections, of central nervous
 system, 799
 Clarithromycin, in neonates, 260
 Clavicular fractures, in labor and delivery,
 851
 Clindamycin, in neonates, 260
 Clomiphene citrate, in ovulation induction,
 325-326, 330
 Clonic seizures, 736, 740
 Clonidine, in hypertension, in pregnancy,
 398
 Coarctation, aortic, pregnancy in, 472-473
 Cocaine exposure, seizures in, 763
 Cognitive deficits, after extracorporeal
 membrane oxygenation, 664, 669-670
 Colonization, of reproductive tract,
Ureaplasma urealyticum in, 92-93
 Color Doppler studies, of brain, 682-683
 Colposcopy, in pregnancy, 371-372
 Coma, in neonates, lack of criteria for, 865
 Computed tomography, in hypoxic-
 ischemic brain injury, 615
 Congenital cardiac disease (adult), in
 neonatal lupus erythematosus,
 297-298
 labor and delivery in, 477-479
 postpartum care in, 479
 preconceptual evaluation of, 475-476
 pregnancy in, 467-482
 aortic disease, 472-473
 complex cyanotic, 473-475
 evaluation of, 468-469
 management in, 476-477
 normal physiologic changes and, 467-
 468
 shunt lesions, 469-471
 valvular lesions, 471-472
 Congenital cardiac disease (neonate),
 807-826
 incidence of, 807
 neurologic injury in, acquired, 808
 congenital, 815-818
 future trends in, 818-819
 intraoperative, 809-812
 postoperative, 812-815
 preoperative, 808-809
 surgery in, brain injury in, 809-815
 Congenital diseases. *See specific diseases.*
 Congenital fiber type disproportion,
 838-839
 Conization, cervical, in pregnancy, 372-374
 Consciousness alterations, in hypoxic-
 ischemic brain injury, 610-611
 Contractions, uterine, fetal cerebral
 hemodynamics and oxygenation
 during, 552-555
 Contrast agents, for ultrasonography, 688
 Corneal reflex, evaluation of, in brain
 death, 863, 865
 Cortical development, magnetic resonance
 imaging of, 699-702
 Corticosteroids, antenatal, intraventricular
 hemorrhage and, 595
 in asthma, in pregnancy, 418
 in preterm premature rupture of mem-
 branes, 51
 in systemic lupus erythematosus, in
 pregnancy, 299
 Coxsackie virus infections, 203
 of central nervous system, 794-795
 Cranial injury, in labor and delivery,
 846-848
 Cranial nerve injury, in labor and delivery,
 848-849
 Culture, of herpes simplex virus, 140
 of *Ureaplasma urealyticum*, 98-99
 Cushing's syndrome, pregnancy in,
 hypertension in, 394
 Cyanotic heart disease, pregnancy in,
 473-475
 Cyst(s), in periventricular hemorrhagic
 infarction, 570

- in periventricular leukomalacia, 576
- Cystitis**, in pregnancy, bacterial, 348
 - interstitial, 351–352
- Cystometry**, in pregnancy, 353–354
- Cystoplasty**, augmentation, pregnancy after, 359–360
- Cytochrome oxidase**, deficiency of, cardiac and neurologic disorders in, 818
 - myopathies in, 840
- redox state of**, measurement of, 541
- Cytokines**, in infections, 501–502
 - in periventricular leukomalacia pathogenesis, 582
- Cytomegalovirus infections**, 151–160
 - brain injury in, 788–789
 - magnetic resonance imaging of, 712
 - epidemiology of, 152–153
 - in fetus, 154–156, 278–279
 - in neonates, 156–157, 279–280, 788–789
 - in pregnancy, 153–154, 278–279
 - prevention of, 157–158
 - treatment of, 157, 278–280
 - vaccination for, 241
 - virus characteristics in, 151–152
- Death, brain.** *See Brain death.*
 - in neonatal infections, causes of, 8–10
 - epidemiology of, 1–4
 - sexually transmitted, 25
 - in seizures, 765
 - in streptococcal infections, group B, 797
 - perinatal, terminology of, 25
- Decortication**, versus subcortical seizures, 748–749
- Deep hypothermic circulatory arrest**, in cardiac surgery, neurologic injury from, 807, 809–815
- Delivery.** *See Labor and delivery.*
 - fetal cerebral hemodynamics and oxygenation during. *See under Fetus.*
 - hypoxic insults during, 609–610
- Demyelinating disorders**, 830
- Dermatitis, atopic**, in pregnancy, 427–429
- de Toni-Fanconi-Debre syndrome**, 840
- Developing countries**, neonatal infections
 - in, epidemiology of, 1–8
 - mortality in, 1–4, 8–10
 - omphalitis, 5–6
 - pathogens causing, 6–8
 - preventive strategies for, 10–14
 - respiratory, 4
 - tetanus, 4–5
- Development**, of brain, magnetic
 - resonance imaging of, 699–706
 - functional, 702–703
 - in disorders, 707–708
 - structural, 699–702
 - magnetic resonance spectroscopy of, 703–706
- Dextromethorphan**, in hypoxic-ischemic brain injury prevention, 638
- Dextrorphan**, in hypoxic-ischemic brain injury prevention, 638
- Di George syndrome**, cardiac and neurologic manifestations of, 817
- Diabetes mellitus**, in adults, versus maternal nutrition, 443
 - nephropathy in, pregnancy in, 489
- Dialysis**, renal, pregnancy in, 360–361, 493–494
- Diaphragmatic hernia**, extracorporeal membrane oxygenation in, versus neurodevelopmental outcome, 668–669
- Diarrhea**, in developing countries, 6 vaccination for, 240–241
- Diet.** *See also Nutrition.*
 - in pregnancy, in hypertension, 401
 - in urethral syndrome, 351
- Diffuse cognitive phenomena**, birth trauma and, 848
- Diffusion-weighted magnetic resonance imaging**, 696–697, 702
 - in hypoxic-ischemic brain injury, 615–616
- Digital subtraction angiography**, in brain death determination, 874–875
- 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzoquinazoline (NBQX)**, in hypoxic-ischemic brain injury prevention, 639
- Disseminated intravascular coagulation**, in septic shock, 223
- Dissociation**, electroclinical, 749, 752
- Diuretics**, in hypertension, in pregnancy, 399–400
- Dizocilpine (MK-801)**, in hypoxic-ischemic brain injury prevention, 638
- DNA analysis**, in inborn errors of metabolism, 776
- Doppler studies**, of brain, 682–683
 - fontanelle compression technique in, 685–687
 - in brain death determination, 873
 - in hydrocephalus, 685–687
 - venous system, 683–685
- Down syndrome (trisomy 21)**, cardiac and neurologic manifestations of, 816
 - pregnancy in, 462–463
- Drug withdrawal**, seizures in, 763
- Ductus arteriosus, patent**, pregnancy in, 470–471
- Dural sinuses**, ultrasonography of, 683–685
- Dysgenesis**, cerebral, in cardiac disease, 816
- Early myoclonic encephalopathy and early infantile epileptic encephalopathy (OHTAHARA syndrome)**, seizures in, 764

- Ebstein's anomaly, pregnancy in, 474
 Echocardiography, in congenital cardiac disease, in pregnancy, 469
 Echoviruses, infections of central nervous system, 794–795
 ECMO. *See Extracorporeal membrane oxygenation.*
 Ectopic pregnancy, after fertility treatments, 323
 Edema, angio-, pregnancy in, 424–427
 in pre-eclampsia, 392
 Education, maternal, in neonatal infection prevention, 12
 Electrocardiography, in congenital cardiac disease, in pregnancy, 469
 Electroclinical dissociation, 749, 752
 Electroencephalography, in brain death determination, 869–871
 in extracorporeal membrane oxygenation, 657–659
 in seizures, 744–748
 clonic, 740
 duration and, 746–747
 focal, 748–750
 fragmentary, 738–739
 multifocal, 748–750
 myoclonic, 742–743
 patterns of, 746, 748
 periodic discharges in, 748
 tonic, 741
 interictal, 744, 746
 Embolism, hypoxic-ischemic brain injury in, 608, 614
 Embryo(s), transfer of, in assisted reproductive technology, 326–329
 Embryopathy, rubella, 796
 varicella, 792–794
 Encephalitis, magnetic resonance imaging of, 712
 Encephalopathy, hypoxic-ischemic. *See Hypoxic-ischemic brain injury.*
 in inborn errors of metabolism, 773–786
 amino acid oxidation disorders, 777–780
 diagnosis of, 774–777
 fatty-acid oxidation disorders, 781–782
 lactic acidosis, 782–783
 lysosomal disorders, 784
 magnetic resonance imaging of, 707, 709
 organic acidemias, 780–781
 peroxisome disorders, 783–784
 pyridoxine (vitamin B₆) dependency, 761, 783
 in OHTAHARA syndrome, 764
 postasphyxial, 754–755
 Endocarditis, risks of, in congenital cardiac disease, 478
 Endotoxin, in septic shock, 222
 Energy metabolism, cerebral. *See Cerebral energy metabolism.*
 Energy requirements, of pregnancy, 435–436
 Enterovirus infections, 203–208
 clinical manifestations of, 204
 differential diagnosis of, 206
 epidemiology of, 204
 in neonates, 204–206
 of central nervous system, 794–795
 treatment of, 206–207
 vaccination for, 207–208
 virus characteristics in, 203
 Enzyme assays, in inborn errors of metabolism, 776
 in syphilis, 79, 81
 Eosinophilic cystitis, pregnancy in, 352
 Epileptic encephalopathy, in OHTAHARA syndrome, 764
 Episiotomy, effects of, 364–365
 Erythema infectiosum (parvovirus B19 infections), 197–199
 Erythromycin, in neonates, 260
 in *Ureaplasma urealyticum* infections, 98
Escherichia coli infections, of central nervous system, 799
 Ethambutol, in tuberculosis, 119, 121
 Evolutionary perspective, of maternal-placental-fetal interactions with microbial species, 498–502
 Exchange transfusion, in neonatal sepsis, 219–220
 Excitation, in MRI, 694
 Excitatory amino-acid antagonists, in hypoxic-ischemic brain injury, 620
 Excitotoxicity theory, of hypoxic-ischemic brain injury, 629–632, 634
 Extracorporeal membrane oxygenation, 655–675
 brain injury mechanisms in, 656
 outcome of, at early school age, 669–670
 prognostic signs in, 657–659
 versus cardiorespiratory failure cause in, 668–669
 usage statistics on, 655
 venoarterial, brain injury in, 659–662
 brainstem auditory evoked potentials in, 659
 clinical features of, 662–668
 electroencephalography in, 657–659
 right common carotid artery ligation and reconstruction in, 559–662
 venovenous, clinical features of, 668
- Fallot, tetralogy of, pregnancy in, 473
 Familial seizures, 764
 Fat, dietary, in pregnancy, 436–437
 Fatal infantile myopathy, 840
 Fatty-acid oxidation disorders, encephalopathy in, 781–782, 817–818

- myopathies in, 840–841
 Fertility problems. *See Infertility.*
 Fetal origins hypothesis, maternal nutrition and, 440–444
 Fetus(es), antibiotic effects on, 251–252
 cerebral hemodynamics and oxygenation in, 547–565
 calculations for, 557–558
 during delivery, 556–557
 future developments in, 562–563
 in hypoxia, animal studies of, 549–550
 near-infrared spectroscopy measurement of. *See Near-infrared spectroscopy.*
 oxytocin effects on, 555–556
 surveillance of, 550, 552
 data collection and analysis problems in, 558–562
 uterine activity effects on, 552–556
 chickenpox in, 277
 congenital heart disease risks in, 476
 cytomegalovirus infections in, 154–156, 278–279
 growth restriction in. *See Intrauterine growth retardation.*
 heart rate of, during uterine contractions, 552–555
 HIV transmission to, 162–163
 hypoxic insults to, 609–610
 immunization effects on, 232
 macrocephalic, in neurofibromatosis, 455
 maternal disease effects on, asthma, 412–414
 Down syndrome, 462–463
 Ebstein's anomaly, 474
 hypertension, 395
 infections. *See Infections, maternal-placental-fetal interactions in.*
 kidney disease, 493
 Marfan syndrome, 457
 neurofibromatosis, 455–456
 renal insufficiency, 486–488
 systemic lupus erythematosus, 295–298, 491
 tetralogy of Fallot, 473
 Turner syndrome, 461–462
 maternal nutrition effects on, 440–444
 folate, 437
 vitamin A, 437–439
 monitoring of, in maternal hypertension, 402
 multiple. *See Multiple gestations.*
 neural tube defects in, folate and, 437
 parvovirus B19 infections in, 198–199
 radiation exposure to, in cervical cancer treatment, 375–376
 reduction of, in multiple gestations, 331–332
 sexually transmitted diseases in. *See Sexually transmitted diseases.*
- syphilis in. *See Syphilis, congenital.*
 tuberculosis in. *See Tuberculosis, congenital.*
 vitamin A effects on, 437–439
 Fibrinolytic therapy, for hydrocephalus prevention, after intraventricular hemorrhage, 599
 Fibroids, uterine, treatment for, pregnancy after, 332–333
 Fifth disease (parvovirus B19 infections), 197–199, 796
 Fistulas, genitourinary, in labor and delivery, 356
 Fluid homeostasis, in pregnancy, 484
 Folate, in pregnancy, 437
 Follicle-stimulating hormone, age-related changes in, 336
 in ovulation induction, 324–326, 330–331
 Fontanelle compression technique, in ultrasonography, 685–687
 Foramen ovale, patent, embolic stroke in, 614
 Forceps delivery, cranial injury from, 846–847
 Fractures, in labor and delivery, clavicular, 851
 skull, 847
 Free radicals, in white matter injury, in periventricular leukomalacia, 581–582
 inhibition of, in hypoxic-ischemic brain injury prevention, 641–642
 Frequency, urinary, in pregnancy, 345
 Fukuyama muscular dystrophy, 834
 Fungal infections, of central nervous system, 803–804
- β -Galactosidase deficiency, encephalopathy in, 784
 Gamma-aminobutyric acid receptor agonists, in hypoxic-ischemic brain injury prevention, 640
 Gamma-D-glutamylglycine, in hypoxic-ischemic brain injury, 620
 Ganciclovir, in cytomegalovirus infections, 157, 279–280
 Gangliosidosis, encephalopathy in, 784
 Genetic disease, pregnancy in, 451–465
 Marfan syndrome, 456–459, 472–473
 neurofibromatosis type 1, 451–456
 trisomy 21 (Down syndrome), 462–463
 Turner syndrome, 459–462
 47,XXX syndrome, 463
 Genital diseases. *See also Urogenital disorders.*
 herpes, 130–131, 268–271
 Genital herpes, obstetric management in, 142–145
 Gentamicin, in neonates, 254–255

- Gestational age, versus brain malformations, 708
- Giant axonal neuropathy, 830
- Glomerulonephritis, chronic, pregnancy in, 489
- Glucose, concentration of, cerebral blood flow and, 536
- metabolism of, magnetic resonance spectroscopy of, 706
- Glucose intolerance, in adults, versus maternal nutrition, 443
- Glutamate, in hypoxic-ischemic brain injury, 629, 634
- inhibition of, 636–637
- magnetic resonance spectroscopy of, 716
- metabolism of, magnetic resonance spectroscopy of, 705–706
- Glutamate-receptor antagonists, in hypoxic-ischemic brain injury prevention, 637–639
- Glutamine metabolism, magnetic resonance spectroscopy of, 705–706
- Glutaric aciduria type II, encephalopathy in, 782
- Glycine agonists, in hypoxic-ischemic brain injury prevention, 638
- Glycine encephalopathy, 779
- Glycogen storage diseases, cardiac and neurologic manifestations of, 818
- myopathies in, 839–840
- Glycogenoses, myopathy in, 841
- β_2 -Glycoprotein-I, in antiphospholipid syndrome, 305
- Gonadal dysgenesis, in Turner syndrome, pregnancy in, 459–462
- Gonadotropins, in ovulation induction, 324–326, 330–331
- Gonorrhea, preterm birth and, 33
- Gram-negative organisms, in neonatal infections, 7–8
- Granulocyte(s), transfusion of, in neonatal sepsis, 217–218
- Granulocyte colony-stimulating factor, in neonatal sepsis, 218
- Granulocyte-macrophage colony-stimulating factor, in neonatal sepsis, 219
- Gray matter, differentiation of, magnetic resonance imaging of, 699–702
- disorders of, in metabolic disorders, magnetic resonance imaging of, 709
- Great arteries, transposition of, pregnancy in, 473–474
- Growth retardation, intrauterine. *See* *Intrauterine growth retardation*.
- Haemophilus influenzae* type B infections, vaccination for, 238–240
- Hearing assessment, in brain death determination, 865
- Hearing loss, after extracorporeal membrane oxygenation, 664, 666–670
- brainstem auditory evoked potentials and, 659
- Heart block, congenital, in neonatal lupus erythematosus, 297–298
- pregnancy in, 475
- Heart disease. *See* *Cardiovascular disorders; Congenital cardiac disease*.
- Heart rate, fetal, during uterine contractions, 552–555
- Hematomas, head, in labor and delivery, 847–848
- Hemodynamics, in fetus. *See Fetus, cerebral hemodynamics and oxygenation in.*
- in pregnancy, 467–468
- Hemofiltration, with plasma exchange, in neonatal sepsis, 220–221
- Hemoglobin oxygen saturation, in fetus, during contractions, 552–555
- Hemorrhage, cerebellar, ultrasonography of, 680–681
- cerebral, seizures in, 757
- hypoxic-ischemic brain injury in, 608
- in neurofibromatosis, 453
- intracranial. *See* *Intracranial hemorrhage; Intraventricular hemorrhage*.
- subarachnoid, ultrasonography of, 681
- subependymal, in extracorporeal membrane oxygenation, 660
- Heparin, in antiphospholipid syndrome, 308–309
- Hepatitis A, in neonates, 186–188
- Hepatitis B, in neonates, 181–191
- natural history of, 183
- transmission to, 182
- prevention of, 183–186
- vaccination for, 183–186
- in pregnancy, transmission to infant, 182
- prevention of, 183–185
- vaccination for, 183–186, 234–235
- Hepatitis C, in neonates, 188
- Hepatitis E, in neonates, 189
- Hereditary angioneurotic edema, in pregnancy, 424–427
- Hernia, diaphragmatic, extracorporeal membrane oxygenation in, versus neurodevelopmental outcome, 668–669
- Herpes simplex virus infections, 129–150
- genital, 130–131, 268–271
- obstetric management in, 142–145
- neonatal, brain injury in, 789–792
- clinical features of, 132–138, 790
- diagnosis of, 140–141, 791
- differential diagnosis of, 141
- immunobiology of, 138–139
- incidence of, 131, 789–790
- pathogenesis of, 131–132

- prevention of, 145, 271–272
 prognosis for, 276, 791–792
 treatment of, 141–142, 272–275, 277,
 791–792
- virus characteristics in, 129–130
- Herpes zoster**, 194, 277
- Hesitancy, urinary**, in pregnancy, 347
- Heterotopic pregnancy**, after fertility treatments, 323
- High-frequency ventilation**, intraventricular hemorrhage and, 593–594
- HIV infection**. *See Human immunodeficiency virus infection.*
- Hives (urticaria)**, in pregnancy, 423–427
- Human immunodeficiency virus infection**, 161–180
 breastfeeding during, 12
 in neonates, 280, 795–796
 clinical features of, 795
 diagnosis of, 795
 epidemiology of, 161–162, 795
 management of, 172–174, 795–796
 transmission to, 162–165, 499, 509, 795
 prevention of, 167–172
 in pregnancy, 280
 clinical evaluation of, 166–167
 counseling on, 165–166
 epidemiology of, 161–162
 screening for, 165–166
 transmission to infant, 162–165, 499, 509, 795
 prevention of, 167–172
 syphilis with, diagnosis of, 79
 transmission of, 74
 tuberculosis with, 109–110
- Human parvovirus B19 infections**, 197–199
 of central nervous system, 796
- Human T-cell leukemia virus type 1**, maternal-child transmission of, 499–500
- Hydralazine**, in hypertension, in pregnancy, 398, 402
- Hydrocephalus**, after intraventricular hemorrhage, brain injury in, 600–602
 management of, 598–600
 pathogenesis of, 596–598
 prevention of, 598–600
 in neurofibromatosis, 455
 ultrasonography of, 680, 685–687
- Hydrocortisone**, in systemic lupus erythematosus, in pregnancy, 299
- Hydrogen-1**, in magnetic resonance spectroscopy, 699, 703–706, 875
- Hyperammonemia**, encephalopathy in, 777–778
- Hyperbilirubinemia**, brain injury in, magnetic resonance spectroscopy of, 710–711
- Hyperglycinemia, nonketotic**, encephalopathy in, 779
 magnetic resonance imaging of, 710
- Hypermyelination**, in hypoxic-ischemic brain injury, 612
- Hypernatremia**, seizures in, 756
- Hyperoxemia**, cerebral blood flow in, 532
- Hyperplexia**, versus seizures, 744–745
- Hypertension**, cerebral blood flow in, 535
 control of, in hypoxic-ischemic brain injury, 619
 in pregnancy, 391–406. *See also Preeclampsia.*
 activity restriction in, 401
 blood pressure measurement technique in, 392–393
 calcium supplements and, 440
 categories of, 391
 counseling on, 401
 definition of, 391–392
 diagnostic criteria for, 391–392
 diet in, 401
 differential diagnosis of, 393–394
 evaluation of, 400–401
 fetal risks in, 395
 in kidney disease, 492
 in neurofibromatosis, 454
 in systemic lupus erythematosus, 294–295
 maternal risks in, 395–396
 mild, 396–397
 monitoring in, 401–402
 postpartum management of, 402–403
 treatment of, 396–400, 402–403, 492
 intraventricular hemorrhage in, 590–591
 pulmonary, pregnancy in, 469–470
- Hyperventilation**, cerebral blood flow in, 532
- Hypocalcemia**, seizures in, 756
- Hypocarbia**, in extracorporeal membrane oxygenation, versus sequelae, 666
- Hypoglycemia**, cerebral blood flow in, 535–536
 seizures in, 756
- Hypomyelinating neuropathy**, 830
- Hyponatremia**, seizures in, 756
- Hypoparathyroidism**, seizures in, 756
- Hypoplastic left heart syndrome**, cerebral dysgenesis in, 816
- Hypotension**, cerebral blood flow in, 534–535
 control of, in hypoxic-ischemic brain injury, 618–619
 in extracorporeal membrane oxygenation, versus sequelae, 665
 intraventricular hemorrhage in, 591
- Hypothermia**, in cardiac surgery, neurologic injury from, 807, 809–815
 in hypoxic-ischemic brain injury prevention, 636–637

- Hypotonia, in hypoxic-ischemic brain injury, 611
 in neuromuscular disorders, 827
- Hypoxia and hypoxemia. *See also Asphyxia.*
 brain injury in. *See Hypoxic-ischemic brain injury.*
 cerebral blood flow in, 532
 cerebral hemodynamics and oxygenation in, in fetus, animal studies of, 549–550
 definition of, 607
 vs. uterine contraction frequency, 554–555
- Hypoxic-ischemic brain injury, 607–625, 627–654
 asymptomatic, 610
 brain death in, 863
 brainstem, 611
 cellular mechanisms in, 628–635
 after reperfusion, 632–633
 energy failure in, 629
 excitotoxicity in, 629–632
 focal, 628–629
 global, 628
 morphologic forms of, 633
 vulnerability and, 633–635
 clinical features of, 610–611
 clinical setting for, 609–610
 focal, 613–614
 pathogenesis of, 628–629
 global, in cardiac surgery, 810–812
 pathogenesis of, 628
 imaging in, 614–628
 in congenital heart disease, 809–810
 in extracorporeal membrane oxygenation. *See Extracorporeal membrane oxygenation.*
 insult timing in, 609–610
 magnetic resonance imaging of, 712–717
 multifocal, 613–614
 neuropathology of, 611–614
 parasagittal, 613
 pathogenesis of, 607–608
 cellular mechanisms in, 628–635
 periventricular leukomalacia in. *See Periventricular leukomalacia.*
 prevention of, 618, 635–644, 716–717
 cytosolic calcium accumulation control in, 637–642
 excitatory amino acid accumulation prevention in, 635–637
 future directions in, 643–644
 microvascular-related techniques in, 642–643
 prognosis for, 616, 618, 620–621
 reperfusion after, brain injury in, 809–810
 cellular events after, 632–633
 seizures in, 754–756
 selective neuronal necrosis in, 612
 spectrum of, 610–611
 stages of, 621
 status marmoratus in, 612
 treatment of, 618–620
- Hysterectomy, in cervical cancer, 375–377
- Hysteroscopy, in Asherman syndrome, 334–335
- Iodoxuridine, in herpes simplex virus infections, in neonates, 275
- Imipenem, in neonates, 259
- Immune globulin, in antiphospholipid syndrome, 309
 in enterovirus infections, 207
 in hepatitis A, 187–188
 in neonatal sepsis, 214–217
 in respiratory syncytial virus infections, 202–203
 in varicella zoster virus infections, 194–196, 277–278, 794
- Immunization. *See Vaccination.*
- Immunobiology, of neonates, vaccination and, 241–244
- Immunoblot tests, for syphilis, 79, 81
- Immunoglobulin A nephropathy, pregnancy in, 489–490
- Immunoglobulin E, in allergic reactions, 407–408
- Immunoglobulin G, maternal-child transfer of, 507–508
- Immunology, of infections. *See Infections, maternal-placental-fetal interactions in.*
- Immunotherapy, for allergy, 409
- In vitro fertilization. *See Assisted reproductive technologies.*
- Inborn errors of metabolism. *See Metabolism, inborn errors of.*
- Incontinence, urinary, in pregnancy, 345–347
 surgery for, pregnancy after, 358–359
- Indomethacin, cerebral blood flow effects of, 537–538
 intraventricular hemorrhage and, 591–592, 594–595
- Infarction, cerebral, seizures in, 757
 in hypoxic-ischemic brain injury, 613–614
 periventricular hemorrhagic. *See Periventricular hemorrhagic infarction.*
- Infections, antibacterial therapy for, 251–266
 bacterial sepsis, 213–229
 brain injury in, magnetic resonance imaging of, 712
 central nervous system. *See Central nervous system, infections of.*
 cytomegalovirus. *See Cytomegalovirus infections.*

- global impact of, 1-21
 group B streptococcal. *See Streptococcal infections, group B.*
 hepatitis virus, 181-191
 herpes simplex virus. *See Herpes simplex virus infections.*
 human immunodeficiency virus. *See Human immunodeficiency virus infection.*
 in developing countries. *See Developing countries.*
 in neonates, global impact of, 1-21
 epidemiology of, 1-8
 mortality in, 1-4, 8-10
 pathogens causing, 6-8
 preventive strategies for, 10-13
 treatment of, 13-14
 in periventricular leukomalacia pathogenesis, 582
 intra-amniotic, 43-57
 maternal-placental-fetal interactions in, 497-521
 evolutionary perspective of, 498-502
 particular (Aristotelian) perspective of, 502-516
 fetal defense factors in, 512-516
 maternal factors in, 506-509
 neonatal defense factors in, 512-516
 placental aspect of, 509-512
 time of disease acquisition and, 502-506
 parvovirus, 197-199, 796
 premature rupture of membranes and, 43-57, 171
 respiratory syncytial virus, 193-211
 sexually transmitted diseases, 23-41
 syphilis. *See Syphilis.*
 tuberculosis, 107-127, 236
Ureaplasma urealyticum, 91-105
 urinary tract, in pregnancy, 348-350
 vaccinations for, 231-249
 varicella virus, 193-211, 277-278
 viral. *See also specific infections.*
 treatment of, 267-283
 Infertility, in Turner syndrome, 461
 treatments for, pregnancy after, 321-342
 ectopic, 323
 in uterine dysfunction, 332-335
 multiple, 323-332
 oocyte donation for, 335-338
 spontaneous abortion in, 322-323
 Inflammatory neuropathies, 830-831
 Injury, birth. *See Birth trauma.*
 Intellectual deficits, after extracorporeal membrane oxygenation, 664, 669-670
 in periventricular hemorrhagic infarction, 570
 in periventricular leukomalacia, 576-577
 Intensity-modulated optical spectroscopy, in fetal oxygenation measurement, 561
 Interictal electroencephalography, 744, 746
 Interleukin(s), in septic shock, 222
 Interleukin-6, in periventricular leukomalacia pathogenesis, 582
 Interstitial cystitis, in pregnancy, 351-352
 Intoxication, drug, seizures in, 763
 Intra-amniotic infections, 43-57
 diagnosis of, 45-46
 management of, 46-47
 microbiology of, 44
 outcome of, 47-48
 pathogenesis of, 43-44
 prevention of, 48
 risk factors for, 44
 Intracranial hemorrhage, cerebral blood flow in, 537
 in congenital heart disease, 808-809
 in labor and delivery, 847-848
 magnetic resonance imaging of, 711-712
 seizures in, 757
 Intracranial pressure, regulation of, in hypoxic-ischemic brain injury, 619
 Intrauterine growth retardation, in antiphospholipid syndrome, 301
 in asthma, 413
 in neurofibromatosis, 455
 in sexually transmitted diseases, 25-26
 in systemic lupus erythematosus, 296
 Intraventricular hemorrhage, 589-605
 germinal matrix, 590-596
 interventions for, 591-595
 pathogenesis of, 590-594
 risk factors for, 590-596
 hydrocephalus after, brain injury in, 600-602
 management of, 598-600
 pathogenesis of, 596-598
 ultrasonography of, 680
 incidence of, 589-590
 infarction in. *See Periventricular hemorrhagic infarction.*
 seizures in, 757
 ventriculomegaly after, 596-598
 Iron, in hypoxic-ischemic brain injury, 630-631
 supplementation with, in pregnancy, 439-440
 Ischemia, cerebrovascular, seizures in, 757
 definition of, 607
 Ischemic brain injury. *See Hypoxic-ischemic brain injury.*
 Isoniazid, in tuberculosis, 119-122
 Isovaleric acidemia, encephalopathy in, 780-781
 Jarisch-Herxheimer reaction, in syphilis treatment, 83-84
 Jet ventilation, intraventricular hemorrhage and, 593-594

- Jitteriness, versus seizures, 737, 744
- Keratoconjunctivitis, in herpes simplex virus infections, in neonates, 275
- Ketamine, in hypoxic-ischemic brain injury, 620
- Kety-Schmidt method, for cerebral blood flow measurement, 538
- Kidney, disease of, pregnancy in, 483–496
 calculi, 350
 cancer, 352
 counseling in, 491
 diabetic nephropathy, 489
 dialysis for, 360, 493–494
 glomerulonephritis, 489
 hypertension in, 393
 immunoglobulin A nephropathy, 489–490
 infections, 349–350
 lupus nephropathy, 294, 490–491
 management of, 491–493
 monitoring in, 492
 pregnancy affected by, 486–488
 pregnancy effects on disease, 484–486
 reflux nephropathy, 490
 tubulointerstitial, 490
 versus normal physiologic changes, 483–484
- physiologic changes in, in pregnancy, 483–484
- rupture of, in pregnancy, 352
 transplantation of, pregnancy after, 494
- Kyphoscoliosis, in neurofibromatosis, 456
- Labetalol, in hypertension, in pregnancy, 399
- Labor and delivery, fetal cerebral hemodynamics and oxygenation during. *See under Fetus.*
 hypoxic insults during, 609–610
 in antiphospholipid syndrome, 307–310
 in asthma, 414, 416, 419
 in cervical cancer, 377
 in congenital cardiac disease, 477–478
 in intra-amniotic infections, timing of, 46
 in Marfan syndrome, 458
 in premature rupture of membranes, pre-term, 52
 term, 52–53
 in systemic lupus erythematosus, 298–299
 neonatal infection prevention in, 11–12, 142–145
 neonatal trauma in. *See Birth trauma.*
 preterm. *See Preterm birth.*
- residual genitourinary disorders after, 361–365
- urinary tract injury in, 355–358
- lactic acid, measurement of, in inborn errors of metabolism, 776
- metabolic disorders of, brain involvement in, magnetic resonance spectroscopy of, 709–710
- Lactic acidosis, primary, encephalopathy in, 782–783
- Lamotrigine, in hypoxic-ischemic brain injury prevention, 636
- Larmor equation, in MRI, 694
- Laryngopathia gravidarum, 426
- Lazerooids, in hypoxic-ischemic brain injury prevention, 642
- Leukomalacia, periventricular. *See Periventricular leukomalacia.*
- Lipopolysaccharide, in septic shock, 222
- Listeria monocytogenes* infections, of central nervous system, 797–799
- Local anesthesia, inadvertent fetal injection of, seizures in, 763
- Long-chain acyl-CoA dehydrogenase deficiency, encephalopathy in, 817–818
- Low birthweight infants, neonatal infection risk in, 13
- Lumbar puncture, in hydrocephalus prevention, after intraventricular hemorrhage, 598–600
- Lung infections, in neonates, *Ureaplasma urealyticum* in, 94–97
- Lupus anticoagulant, in antiphospholipid syndrome, 302–304
- Lupus flare, in pregnancy, 293–294
- Lymphocytic choriomeningitis virus infections, 796
- Lysosomal disorders, encephalopathy in, 784
- Macrocephaly, in neurofibromatosis, 455
- Macrolides, in neonates, 260
- Magnesium sulfate, in hypoxic-ischemic brain injury prevention, 639
- intrapartum, in periventricular leukomalacia reduction, 582
- neonatal neuromuscular dysfunction from, 833
- Magnetic dipole moment, in MRI, 694
- Magnetic resonance imaging, 693–723
 after extracorporeal membrane oxygenation, 659–660
 definition of, 694
 diffusion-weighted, 696–697, 702
 functional, 696–697
 of developmental changes, 702–703
 of developmental changes, 699–706
 functional, 702–703

- structural, 699–702
- of neurologic disorders, 707–718
- developmental, 707–708
- in hypoxic-ischemic brain injury, 615–618, 712–717
- in inborn errors of metabolism, 707, 709–711
- in infections, 712
- in intracranial hemorrhage, 711–712
 - versus outcome, 717–718
- perfusion, 697, 702–703
- postprocessing techniques in, 695–696
- principles of, 694–699
- quantitative measurements in, 695–696
- structural, 694–695
 - of developmental changes, 699–702
- three-dimensional, 701–702
- Magnetic resonance spectroscopy, 697–699
 - definition of, 694
 - in neurodevelopmental outcome prediction, 718
 - of brain disorders, in metabolic disorders, 709–711
 - of cerebral metabolism, in brain death determination, 875
 - in hypoxic-ischemic brain injury, 715–716
 - of developmental changes, 703–706
 - of intracranial hemorrhage, 712
- Malaria, cerebral, in neonates, 803
- Malformations, central nervous system, seizures in, 759–760
- Malnutrition, in pregnancy, management of. *See Nutrition, in pregnancy.*
- Mantoux test, in pregnancy, 113–114
- Maple syrup urine disease, encephalopathy in, 778–779
- Marfan syndrome, pregnancy in, 456–459, 472–473
- Mastoid approach to posterior fossa, ultrasonography of, 677–682
- Mechanical ventilation, intraventricular hemorrhage and, 593–594
- Meconium aspiration syndrome, extracorporeal membrane oxygenation in, versus neurodevelopmental outcome, 669
- Megalencephaly, in metabolic disorders, magnetic resonance imaging of, 709
- Memantine, in hypoxic-ischemic brain injury prevention, 638–639
- Membrane(s), premature rupture of. *See Premature rupture of membranes.*
- Membrane composition, of neurons, magnetic resonance spectroscopy of, 703–704
- Membrane depolarization, prevention or delay of, in hypoxic-ischemic brain injury, 635–636
- Meningitis, neonatal, *Citrobacter*, 799
- epidemiology of, in developing countries, 3–4
- Listeria monocytogenes*, 797–799
- magnetic resonance imaging of, 712
- pathogens causing, 6–8
- Ureaplasma urealyticum* in, 97–98
- Mental retardation, after extracorporeal membrane oxygenation, 664, 667
- Meropenem, in neonates, 259
- Metabolism, cerebral. *See Cerebral energy metabolism.*
- inborn errors of, myopathies in, 839–841
- neurologic dysfunction in, 773–786
 - amino-acid oxidation disorders, 777–780
 - diagnosis of, 774–777
 - fatty-acid oxidation disorders, 781–782
 - lactic acidosis, 782–783
 - lysosomal disorders, 784
 - magnetic resonance imaging of, 707, 709
 - organic acidemias, 780–781
 - peroxisome disorders, 783–784
 - pyridoxine (vitamin B₆) dependency, 761, 783
 - seizures, 760–761
 - with cardiac disease, 817–818
- Methicillin, in neonates, 261
- N-Methyl-D-aspartate receptor, in hypoxic-ischemic brain injury, 629, 634
 - antagonists for, 637–639
- Methyldopa, in hypertension, in pregnancy, 397, 402
- Methylmalonic acidemia, encephalopathy in, 780
- Metronidazole, in neonates, 260–261
- Metroplasty, pregnancy after, 333–334
- Mezlocilllin, in neonates, 262
- Microbubble contrast agents, for ultrasonography, 688
- Microorganisms, maternal-placental-fetal interactions with, evolutionary perspective of, 498–502
- Microvascular occlusive lesions, in hypoxic-ischemic brain injury, management of, 642–643
- Migration anomalies, of brain, in metabolic disorders, magnetic resonance imaging of, 709
- Mitral regurgitation, pregnancy in, 473
- Molybdenum cofactor deficiency, encephalopathy in, 779–780
- Monoclonal antibodies, in septic shock, 222
- Motor unit disorders. *See Neuromuscular disorders.*
- MRI. *See Magnetic resonance imaging.*
- Multiple gestations, after fertility treatments, 323–332

- Multiple gestations (*Continued*)
 frequency of, 326-329
 multifetal reduction in, 331-332
 outcome of, 329
 ovarian physiology and, 323-324
 ovulation-inducing agents and, 324-326
 prevention of, 330-331
- Muscle-eye-brain disease, 835
- Muscular disorders. *See Neuromuscular disorders.*
- Muscular dystrophies, 833-836
- Myasthenia, acquired autoimmune, 831
 congenital syndromes, 831-832
 transient neonatal, 831
- Mycobacterium tuberculosis* infections. *See Tuberculosis.*
- Myelination, disorders of, 830
 of brain, excessive, in hypoxic-ischemic brain injury, 612
 magnetic resonance imaging of, 699-702
- Myoclonic encephalopathy, in OHTAHARA syndrome, 764
- Myoclonic seizures, 737, 742-743
- Myoclonus, in sleep, versus seizures, 737
 stimulus-evoked, versus seizures, 744-745
- Myoinositol, magnetic resonance spectroscopy of, 706
- Myomectomy, uterine, pregnancy after, 332-333
- Myopathies, congenital, 836-841
 central core disease, 837-838
 centronuclear/myotubular, 838
 fiber type disproportion, 838-839
 nemaline, 837
- Myotonic dystrophy, 835-836
- Myotubular myopathy, 838
- Nafcillin, in neonates, 261
- Natural killer cells, in herpes simplex virus infections, 139
- NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzoquinoline), in hypoxic-ischemic brain injury prevention, 639
- Near-infrared spectroscopy, in fetal cerebral hemodynamics and oxygenation measurement, 547-565
 apparatus for, 549
 calculations for, 557-558
 data collection and analysis problems in, 558-562
 during delivery, 556-557
 during uterine contractions, 552-555
 future developments in, 562-563
 in animal studies, 549-550
 oxytocin effects on, 555-556
- safety of, 552
 technique for, 550, 552
 theory of, 548-549
- Neck, spinal cord injury in, in labor and delivery, 849-850
- Necrosis, of neurons, in hypoxic-ischemic brain injury, 612
 of white matter, in periventricular hemorrhage, 568-569
 in periventricular leukomalacia, 574-575, 581-582
- Nemaline myopathy, 837
- Neonates. *See specific disorders and conditions.*
- Nephrolithiasis, pregnancy in, 350
- Nephropathy. *See Kidney, disease of.*
- Nephrotic syndrome, pregnancy in, 492-493
- Neural tube defects, maternal folate intake and, 437
- Neurofibromatosis type 1, pregnancy in, 451-456
 central nervous system tumors in, 453-454
 cutaneous manifestations of, 453
 diagnosis of, 452
 hydrocephalus in, 455
 hypertension in, 454
 inheritance of, 452
 intruterine growth restriction in, 455
 kyphoscoliosis in, 456
 macrocephaly in, 455
 neurofibromas in, 453
 outcome of, 456
 pheochromocytoma in, 454-455
 seizures in, 455-456
- Neurogenic regulation, of cerebral blood flow, 533-534
- Neurologic disorders, brain death, 859-882
 central nervous system infections, 787-806
 cerebral blood flow and metabolism and. *See Cerebral blood flow; Cerebral energy metabolism.*
 in birth trauma, 845-857
 in cardiac disease, 807-826
 in extracorporeal membrane oxygenation, 655-675
 in hypoxic-ischemic brain injury. *See Hypoxic-ischemic brain injury.*
 in premature infants, 567-587
 in intraventricular hemorrhage, 589-605
 intrapartum cerebral hemodynamics and oxygenation and, 547-565
 magnetic resonance imaging in. *See Magnetic resonance imaging.*
 metabolic encephalopathies, 707, 709, 773-786
 neuromuscular, 827-844

- seizures. *See Seizures.*
 ultrasound in. *See Ultrasonography.*
- Neurologic examination, in brain death, 863, 865–868
 apnea testing in, 866–867
 duration of, 867–868
- Neuromuscular disorders, 827–844
 arthrogryposis, 841–842
 botulism, 832–833
 clinical features of, 827
 magnesium intoxication, 833
 metabolic, 839–841
 muscular dystrophies, 833–836
 myasthenia and myasthenic syndrome, 831–832
 myopathies, 836–841
 neuropathies, 830–831
 spinal muscular atrophies, 828–829
 transmission defects in, 831–833
 types of, 828
- Neurons, apoptosis of, in hypoxic-ischemic brain injury, 633
 necrosis of, in hypoxic-ischemic brain injury, 612, 628–635
- Neuropathies, congenital, 830–831
- Neuroprotection, in hypoxic-ischemic brain injury. *See Hypoxic-ischemic brain injury, prevention of.*
- Neutrophils, transfusion of, in neonatal sepsis, 217–218
- Nifedipine, in hypertension, in pregnancy, 399
- Nimodipine, in hypoxic-ischemic brain injury prevention, 640
- Nitric oxide, intraventricular hemorrhage and, 594
- Nitric oxide synthase, in hypoxic-ischemic brain injury, 631–632, 641
 manipulation of, 620
 inhibitors of, in hypoxic-ischemic brain injury, 641
 in septic shock, 223
- Nonketotic hyperglycinemia, encephalopathy in, magnetic resonance imaging of, 710
- Nontreponemal tests, for syphilis, 78–79
- Nose, congestion of, in pregnancy, 419–423
- Nutrition, in pregnancy, 433–449
 calcium supplements in, 440
 caloric cost and, 435–436
 fat intake in, 436–439
 fetal origins hypothesis and, 440–444
 folate in, 437
 iron supplements in, 439–440
 vitamin A teratogenicity and, 437–439
 vitamin B₆ in, 439
 weight gain and, 434–435
- Obstetric management. *See Labor and delivery.*
- OHTAHARA syndrome, seizures in, 764
- Oligodendrocytes, necrosis of, in periventricular leukomalacia, 581–582
- Omphalitis, in developing countries, 5
- Oocyte donation, in assisted reproductive technologies, 335–338
- Ophthalmodynamometer, in fontanelle compression, for ultrasonography, 687
- Optical spectroscopy, intensity-modulated, in fetal oxygenation measurement, 561
- Organic acids, accumulation of, encephalopathy in, 780–781
 measurement of, in inborn errors of metabolism, 776–777
- Ornithine transcarbamoylase deficiency, encephalopathy in, 777–778
 hyperammonemia in, magnetic resonance spectroscopy of, 710
- Oscillatory ventilation, intraventricular hemorrhage and, 593–594
- Ovary, dysgenesis of, in Turner syndrome, pregnancy in, 459–462
 physiology of, 323–324
- Ovulation-inducing agents, 324–326
 fetal number control with, 330–331
 for oocyte donation, 338
 multiple gestation frequency with, 326–329
- Oxygen, deficiency of. *See Asphyxia; Hypoxia and hypoxemia.*
 extraction of, in hypotension, 535
 in apnea testing, in brain death, 866–867
 partial pressure of, in cerebral blood flow regulation, 532
- Oxygen saturation, in fetus, calculation of, 557–558
 during contractions, 552–555
 venous, measurement of, 540–541
- Oxygenation, defects of, in cardiac surgery, 810–812
 extracorporeal. *See Extracorporeal membrane oxygenation.*
 in fetus. *See Fetus, cerebral hemodynamics and oxygenation in.*
 maintenance of, in hypoxic-ischemic brain injury, 619
- Oxyprinol, in hypoxic-ischemic brain injury prevention, 642–643
- Oxytocin, fetal oxygenation and, 555–556
- p24 antigen detection, in HIV-exposed neonates, 173
- Palsy, brachial plexus, in labor and delivery, 850–852
- Pap smear, in pregnancy, 371–372
- Parasagittal cerebral injury, hypoxic-ischemic, 613
- Parvovirus B19 infections, 197–199

- Parvovirus B19 infections (*Continued*)
of central nervous system, 796
- Patent ductus arteriosus, pregnancy in, 470–471
- Patent foramen ovale, embolic stroke in, 614
- Pathogens, maternal-placental-fetal interactions with. *See Infections, maternal-placental-fetal interactions in.*
- Pelvic floor, injury of, in labor and delivery, 357–358
- neuromuscular function of, after pregnancy, 361–365
- Pelvic relaxation surgery, pregnancy after, 359
- Penicillin(s), in intra-amniotic infections, 47
in neonates, 261–262
in syphilis, 81–85
- Pentoxifylline, in septic shock, 222–223
- Perfusion magnetic resonance imaging, 697, 702–703
- Perfusion pressure, cerebral. *See Cerebral perfusion pressure.*
- Perineum, descent of, after pregnancy, 363
injury of, in labor and delivery, 357–358
- Peritoneal dialysis, pregnancy in, 493–494
- Periventricular hemorrhagic infarction, 568–574
clinical features of, 570–572, 613
diagnosis of, 570
neuropathology of, 568–569
pathogenesis of, 572–573
prevention of, 573–574
prognosis for, 571–572
- Periventricular leukomalacia, 574–582, 613
cerebral blood flow in, 580–581
clinical features of, 576–578
description of, 574
diagnosis of, 576
in hypoxic-ischemic brain injury, 613
incidence of, 574
neuropathology of, 574–576
pathogenesis of, 578–582
prevention of, 582
vascular anatomy in, 579–580
white matter vulnerability in, 581–582
- Peroxisome disorders, encephalopathy in, 783–784
- Phenobarbital, brain death determination and, 871
in hypoxic-ischemic brain injury, 620
in seizures, 766
intraventricular hemorrhage and, 592–593
- Phenytoin, in hypoxic-ischemic brain injury prevention, 636
in seizures, 766
- Pheochromocytoma, pregnancy in, hypertension in, 393–394
- neurofibromatosis and, 454–455
- Phosphodiesterase inhibitors, in septic shock, 222–223
- Phosphofructokinase deficiency, myopathy in, 841
- Phospholipid antibodies. *See Antiphospholipid syndrome.*
- Phospholipid metabolism, magnetic resonance spectroscopy of, 703–704
- Phosphorus-31, in magnetic resonance spectroscopy, 698, 703–704, 875–876
- Phosphorylase deficiency, myopathy in, 841
- Phrenic nerve injury, in labor and delivery, 850
- Piperacillin, in neonates, 262
- Pituitary gland, injury of, in labor and delivery, 848
- Placenta, infections and. *See Infections, maternal-placental-fetal interactions in.*
insufficiency of, in antiphospholipid syndrome, 301, 305–307
syphilis infection of, 76
- Placenta previa, bladder involvement in, 356–357
- Plasma exchange, with hemofiltration, in neonatal sepsis, 220–221
- Plasmodium infections, of central nervous system, 803
- Pneumococcal infections, vaccination for, 241
- Pneumonia, in neonates, *Ureaplasma urealyticum* in, 94–95
- Polio, 203
vaccination for, 207–208, 235–236
- Polycythemia, stroke in, 614
- Polymerase chain reaction, in diagnosis of, of herpes simplex virus infections, 140
of syphilis, 80–81
of *Ureaplasma urealyticum* infection, 100
- Polyunsaturated fatty acids, dietary, in pregnancy, 436–437
- Pompe disease, cardiac and neurologic manifestations of, 818
myopathies in, 839–840
- Positron emission tomography, for cerebral blood flow measurement, 539–540
for cerebral energy metabolism studies, 539–540
- Postasphyxial encephalopathy, 754–755
- Posterior fossa, ultrasonography of, mastoid approach to, 677–682
- Power Doppler studies, of brain, 682–683
- Prednisolone, in systemic lupus erythematosus, in pregnancy, 299
- Prednisone, in antiphospholipid syndrome, in pregnancy, 307–308
in systemic lupus erythematosus, in pregnancy, 299

- Preeclampsia, antiphospholipid antibodies and, 301
 calcium supplements and, 440
 in asthma, 413
 in systemic lupus erythematosus, 294–295
 superimposed on chronic hypertension, definition of, 392
 morbidity and mortality in, 396
 pregnancy conclusion in, 403
 prevention of, 403
 treatment of, 396–397
- Pregnancy, age factors in, 335–338
 antibiotics in, 251–252
 chickenpox in, 194–195, 277–278
 chronic conditions in, antiphospholipid syndrome, 291–320
 aortic disease, 472–473
 aortic valve malformation, 471
 asthma and allergy, 407–432
 atrial septal defect, 469–470
 autoimmune disease, 291–320, 490–491
 breast cancer, 369–389
 cervical cancer, 369–389
 congenital cardiac disease, 467–482
 diabetes mellitus, 489
 Ebstein's anomaly, 474
 genetic disease, 451–465
 heart block, 475
 hypertension. *See Hypertension.*
 infertility and, 321–342
 malnutrition, 433–449
 Marfan syndrome, 456–459, 472–473
 neurofibromatosis type 1, 451–456
 patent ductus arteriosus, 470–471
 prosthetic heart valves, 471–472
 pulmonic valve disease, 471
 renal disease, 483–496
 systemic lupus erythematosus, 291–320, 490–491
 tetralogy of Fallot, 473
 transposition of great arteries, 473–474
 tricuspid atresia, 474
 trisomy 21, 462–463
 Turner syndrome, 459–462
 urogenital diseases, 343–368
 ventricular, 474
 ventricular septal defect, 470
 47,XXX syndrome, 463
 cytomegalovirus infections in, 153–154, 278–279
 ectopic, after fertility treatments, 323
 education in, in neonatal infection prevention, 12
 genital herpes simplex virus infections in, 130–131, 268–271
 obstetric management in, 142–145
 group B streptococcal infections in, 59–61
 preterm birth and, 33
 prevention of, 65–68
 hepatitis A in, 186–188
 hepatitis B in, 182–185
 hepatitis C in, 188
 hepatitis E in, 189
 heterotopic, after fertility treatments, 323
 HIV infection in. *See under Human immunodeficiency virus infection.*
 infections in. *See Infections, maternal-placental-fetal interactions in.*
 intra-amniotic infections in, 43–48
 maternal care during. *See Prenatal care.*
 nutrition in, 433–449
 parvovirus B19 infections in, 197–199
 physiologic changes in, cardiovascular, 467–468
 renal, 483–484
 urogenital, 343–345
 premature rupture of membranes in. *See Premature rupture of membranes.*
 sexually transmitted diseases in. *See Sexually transmitted diseases.*
 surrogate, 336–337
 syphilis in. *See Syphilis.*
 tuberculosis in. *See under Tuberculosis.*
Ureaplasma urealyticum infections in. *See under Ureaplasma urealyticum infections.*
 vaccination in. *See Vaccination.*
 viral infections in. *See specific infections.*
 Premature infants, brain injury in, 567–587
 in periventricular hemorrhagic infarction, 568–574
 in periventricular leukomalacia. *See Periventricular leukomalacia.*
 neuropathology of, 567–568
 cerebral blood flow in, regulation of, 532
 intraventricular hemorrhage in. *See Intraventricular hemorrhage.*
 Premature rupture of membranes, complications of, 49–50
 definition of, 48
 diagnosis of, 50
 etiology of, 49
 incidence of, 48
 management of, in HIV infection, 171
 preterm, 50–52
 term, 52–53
 natural history of, 49
 preterm, 48–52
 in systemic lupus erythematosus, 296–297
 risk factors for, 49
 Prenatal care, in neonatal infection prevention, 10
 Prenatal diagnosis, of cytomegalovirus infections, 155–156
 of syphilis, 80
 Preterm birth, after cervical conization, 373–374

- Preterm birth (*Continued*)
 in antiphospholipid syndrome, 301
 in assisted reproductive technology pregnancies, 329
 in asthma, 413
 in multiple gestations, 329
 in sexually transmitted diseases, 25, 32-33
 in syphilis, 75-76
 in systemic lupus erythematosus, 296-297
 premature membrane rupture and, 50-52
 Profilometry, in pregnancy, 354
 Propionic acidemia, encephalopathy in, 780
 Prostaglandin inhibitors, in septic shock, 223
 Prosthetic heart valves, pregnancy with, 471-472
 Proteinuria, in preeclampsia, 392
 Proton magnetic resonance spectroscopy, 699, 703-706, 875
 Protozoan infections, of central nervous system, 803
 Pseudoephedrine, in rhinitis, in pregnancy, 421-422
 Pudendal nerve injury, in labor and delivery, 362-364
 Pulmonary hypertension, persistent, seizures in, 757
 pregnancy in, 469-470
 Pulmonary infections, in neonates, *Ureaplasma urealyticum* in, 94-97
 Pulmonic valve disease, pregnancy in, 471
 Pulse sequence, in MRI, 695
 Pupillary reflexes, evaluation of, in brain death, 863
 Pyelonephritis, in pregnancy, 349-350
 Pyrazinamide, in tuberculosis, 119, 121-122
 Pyridoxine dependency, seizures in, 761, 783
 Pyruvate dehydrogenase deficiency, encephalopathy in, 782-783, 818
 Pyruvic acid, measurement of, in inborn errors of metabolism, 776
- Quadruplets and quintuplets. *See Multiple gestations.*
 Quinolones, in neonates, 263
- Radiation therapy, for cervical cancer, in pregnancy, 375-376
 Radioactive isotopes, in cerebral blood flow measurement, cancer risk from, 541-542
 in brain death determination, 872-873
 Reflexes, brainstem, evaluation of, in brain death, 863, 865
 Reflux nephropathy, pregnancy in, 490
 Relaxation, in MRI, 694-695
 Renal disease. *See Kidney, disease of.*
 Respiratory chain defects, cardiac and neurologic disorders in, 818
 Respiratory disorders, in hypoxic-ischemic brain injury, 611
 Respiratory distress syndrome, extracorporeal membrane oxygenation in, versus neurodevelopmental outcome, 668
 surfactant therapy for, intraventricular hemorrhage and, 593
 Respiratory infections, neonatal, in developing countries, 4
Ureaplasma urealyticum in, 94-97
 Respiratory muscles, paralysis of, in spinal muscular atrophy, 829
 Respiratory syncytial virus infections, clinical manifestations of, 200
 diagnosis of, 201
 epidemiology of, 200
 in neonates, 200-201
 prophylaxis of, 202-203
 treatment of, 201-202
 vaccination for, 238
 virus characteristics in, 199-200
 Retention, urinary, in pregnancy, 347-348
 Retinol, teratogenicity of, 437-439
 Rhinitis, allergic, in pregnancy, 419-423
 Rhinitis medicamentosa, in pregnancy, 419-420
 Ribavirin, in respiratory syncytial virus infections, 201-202
 Rifampin, in neonates, 263
 in tuberculosis, 119, 121-122
 Rubella embryopathy, 796
- Salt, imbalance of, seizures in, 756
 Scalp injury, in labor and delivery, 846-847
 Scoliosis, in neurofibromatosis, 456
 Seizures, 735-771
 after cardiac surgery, 812-813
 causes of, 754-764
 cerebral blood flow in, 537
 clinical correlates for, 752-754
 clonic, 736, 740
 diagnosis of, 735-743, 764
 electrographic criteria for, 744, 746-748
 familial, 764
 fragmentary, 736, 738-739
 in asphyxia, 754-756
 in birth trauma, 848
 in hypocalcemia, 756

- in hypoglycemia, 756
 in neurofibromatosis, 455–456
 incidence of, 748–752
 myoclonic, 737, 742–743
 postasphyxial, 754–755
 prognosis for, 765
 prolonged (status epilepticus), 746–747
 subcortical, versus decortication, 748–749
 subtle, 736
 tonic, 736, 741
 treatment of, 765–767
 versus nonepileptic behaviors, 737, 744
 Selective neuronal necrosis, in hypoxic-ischemic brain injury, 612
Sepsis, neonatal, 213–229
 epidemiology of, in developing countries, 3–4
 exchange transfusion in, 219–220
 granulocyte colony-stimulating factor in, 218
 granulocyte-macrophage colony-stimulating factor in, 219
 intravenous immune globulin in, 214–217
 on-line plasma exchange with hemofiltration in, 220–221
 pathogenesis of, 213–214
 pathogens causing, 6–8
 septic shock in, treatment of, 221–224
Ureaplasma urealyticum in, 98
 white blood-cell transfusion in, 217–218
Septic shock, in neonatal sepsis, treatment of, 221–224
Sexually transmitted diseases, 23–41
 adverse outcomes of, 24–26, 31–32
 bacterial vaginosis, preterm birth and, 33–36
 definition of, 23–24
 onset of, timing of, 28
 preterm birth and, 32–36
 sequelae of, 26–28
 syphilis, 71–90
 transmission of, 28–31
 timing of, 26–28
Shingles (zoster), 194, 277
Shock, septic, in neonatal sepsis, treatment of, 221–224
Shunt, ventriculoperitoneal, in hydrocephalus, 600
Single photon emission tomography, for cerebral blood flow measurement, 539
Single ventricle, pregnancy with, 474
Sinusitis, in pregnancy, 423
Skin lesions, in herpes simplex virus infections, 132
 in neonatal lupus erythematosus, 297–298
 in pregnancy, angioedema, 423–427
 atopic dermatitis, 427–429
 neurofibromatosis, 453
 urticaria, 423–427
Skull fractures, in labor and delivery, 847
Sleep, myoclonus in, versus seizures, 737
SNX-111 (calcium channel blocker), in hypoxic-ischemic brain injury prevention, 640
Socioeconomic factors, in neonatal infection prevention, 12
Sodium channel blockers, in hypoxic-ischemic brain injury prevention, 636
Sodium homeostasis, in pregnancy, 484
Spasticity. *See Cerebral palsy*.
Spectroscopy, magnetic resonance. *See Magnetic resonance spectroscopy*.
near-infrared. *See Near-infrared spectroscopy*.
optical, intensity-modulated, in fetal oxygenation measurement, 561
Spinal cord injury, in cardiac surgery, 815
 in labor and delivery, 849–850
Spinal muscular atrophies, 828–829
Status epilepticus, 746–747
Status marmoratus, in hypoxic-ischemic brain injury, 612
Stillbirth, in syphilis, 75
Stimulus-evoked myoclonus, versus seizures, 744–745, 762–763
Stones, kidney, pregnancy in, 350
Storage disorders, cardiac and neurologic manifestations of, 818
Streptococcal infections, group B, 59–70
 in neonates, 7–8, 61–65, 797
 prevention of, 65–68
 in pregnancy, 59–61
 preterm birth and, 33
 prevention of, 65–68
 vaccination for, 237
Streptococcus agalactiae infections, of central nervous system, 797
Streptomycin, in tuberculosis, 119, 121
Stress incontinence, in pregnancy, 346
Stroke, in antiphospholipid syndrome, 302
 in cardiac disease and cardiac surgery, 813–815
 in hypoxic-ischemic brain injury, 611, 613–614
 seizures in, 757
Subarachnoid hemorrhage, ultrasonography of, 681
Subclavian steal, in extracorporeal membrane oxygenation, 661
Subcortical seizures, versus decortication, 748–749
Subgaleal hematoma, 847
Sulfite oxidase deficiency, encephalopathy in, 779–780
Superoxide dismutase, in hypoxic-ischemic brain injury prevention, 641–642
Surfactant therapy, intraventricular hemorrhage and, 593

- Surgery, on urogenital tract, pregnancy after, 358–361
- Surrogacy, in pregnancy, 336–337
- Sympathetic nervous system, in cerebral blood flow regulation, 533–534
- Sympathomimetic agents, in intraventricular hemorrhage prevention, 591
- Syphilis, congenital, clinical manifestations of, 76–78
diagnosis of, 80–81
epidemiology of, 72–73
prevention of, 85–86
transmission of, 73–74
treatment of, 81–85
in pregnancy, 71–90
 clinical manifestations of, 75–78
 diagnosis of, 78–81
 epidemiology of, 71–73
 pathogenesis of, 73–74
 prevention of, 85–86
 treatment of, 81–85
 vertical transmission of, 73–74
- Systemic lupus erythematosus, pregnancy in, 292–299
 antibodies associated with, 292
 diagnostic criteria for, 292–293
 epidemiology of, 292
 fetal outcome in, 295–298
 kidney disease in, 294
 loss of, 295–296
 lupus flare in, 293–294
 management of, 298–299
 maternal outcome in, 293–295
 neonatal lupus erythematosus and, 297–298
 nephropathy in, 490–491
 obstetric management in, 298–299
 preeclampsia in, 294–295
 preterm birth in, 296–297
- T lymphocytes, function of, in neonates, 242–244
 in fetal and neonatal defense system, 507, 512, 515–516
- Teratogenicity, of antibiotics, 251–252
 of vitamin A, 437–439
 of warfarin, 476
- Tetanus, neonatal, in developing countries, 4–5
 maternal vaccination for, 233–234
- Tetralogy of Fallot, pregnancy in, 473
- Theophylline, in asthma, 414
- Thrombocytopenia, autoimmune, in antiphospholipid syndrome, 302
- Thrombolytic agents, in hypoxic-ischemic brain injury prevention, 642
 in stroke, from cardiac disease or surgery, 815
- Thrombosis, hypoxic-ischemic brain injury in, 608, 614
 revascularization in, 642
- in antiphospholipid syndrome, 302, 305–307
- venous sinus, ultrasonography of, 681–682
- Ticarcillin, in neonates, 261–262
- Tirilazad, in hypoxic-ischemic brain injury prevention, 642
- Tobramycin, in neonates, 254–255
- Tocolytic therapy, in intraventricular hemorrhage prevention, 591
 in preterm premature rupture of membranes, 51
- intrapartum, in periventricular leukomalacia reduction, 582
- Tonic seizures, 736, 741
- TORCH organisms, in central nervous system infections, seizures in, 757
- Toxoplasmosis, brain injury in, 802
 magnetic resonance imaging of, 712
- Tracheectomy, in cervical cancer, 376
- Transfusion, in neonatal sepsis, exchange, 219–220
 white blood-cell, 217–218
- Transplantation, kidney, pregnancy after, 494
- Transposition of great arteries, pregnancy in, 473–474
- Trauma, birth. *See Birth trauma.*
- Tremors, versus seizures, 737, 744
- Treponema pallidum* infections. *See Syphilis.*
- Treponemal tests, for syphilis, 79
- Tricuspid atresia, pregnancy in, 474
- Tricuspid regurgitation, in Ebstein's anomaly, pregnancy in, 474
- Trifluorothymidine, in herpes simplex virus infections, in neonates, 275
- Trimethoprim-sulfamethoxazole, in neonates, 263
- Tripeptenamine, in allergic reactions, in pregnancy, 426
- Triplets. *See Multiple gestations.*
- Trisomies, cardiac and neurologic manifestations of, 816–817
- Trisomy 21 (Down syndrome), cardiac and neurologic manifestations of, 816
 pregnancy in, 462–463
- Trypanosomiasis, of central nervous system, 803
- Tuberculin skin test, in pregnancy, 113–114
- Tuberculosis, 107–127
 congenital, clinical manifestations of, 116–118
 transmission of, 110–111
 treatment of, 122
 epidemiology of, 108–110
 in pregnancy, clinical manifestations of, 115–117

- interaction of, 112–113
- pathogenesis of, 110–111
- screening for, 113–115
- treatment of, 118–123
- natural history of, 108
- vaccination for, bacillus Calmette-Guerin in, 118–119, 236
- Tubulointerstitial disease, pregnancy in,** 490
- Tumor(s), central nervous system, in neurofibromatosis,** 453–454
- Tumor necrosis factors, in periventricular leukomalacia pathogenesis,** 582
 - in septic shock, 222
- Turner syndrome, pregnancy in,** 459–462
- Twins. See *Multiple gestations.***

- Ultrasonography, 677–691**
 - contrast agents for, 688
 - fontanelle compression technique in, 685–687
 - in hemorrhage, posterior fossa, 680–681
 - subarachnoid, 681
 - in hydrocephalus, 680, 685–687
 - in hypoxic-ischemic brain injury, 614–615
 - in periventricular hemorrhagic infarction, 570
 - in periventricular leukomalacia, 576
 - in venous sinus thrombosis, 681–682
 - of posterior fossa, mastoid approach to, 677–682
 - of venous system, 683–685
 - power Doppler, 682–683, 685–687
- Umbilical cord, syphilis infection of,** 76
- Urea cycle disorders, encephalopathy in,** 777–778
- Ureaplasma urealyticum* infections, 91–105**
 - culture in, 98–99
 - diagnosis of, 98–100
 - in neonates, antibiotics in, 98
 - meningitis, 97–98
 - pulmonary, 94–97
 - sepsis, 98
 - in pregnancy, antibiotics in, 93–94
 - bacterial vaginosis and, 93
 - colonization and, 92–93
 - rules of evidence for, 91–92
- Ureter, changes of, in pregnancy,** 344–345, 354–355
- Urethra, changes of, in pregnancy,** 344
- disorders of, in pregnancy,** 350–351
 - intrapartum, 355–357
 - postpartum, 361
- Urethrocytometry, in pregnancy,** 354
- Urethrotomitis, in pregnancy,** 350–351
- Urge incontinence, in pregnancy,** 345–346
- Urinary diversion, pregnancy after,** 360

- Urination, problems with, in pregnancy,** 345–348
- Urodynamics, in pregnancy,** 353–355
- Urogenital disorders, in pregnancy,** 343–368
 - intrapartum, 355–358
 - normal physiologic changes and, 343–345
 - residual abnormalities after, 361–365
 - symptoms of, 345–348
 - types of, 348–353
 - urodynamic studies of, 353–355
 - with prior surgery, 358–362
- Urticaria, in pregnancy,** 423–427
- Uterus, adhesions in (Asherman syndrome), pregnancy in,** 334–335
 - anomalies of, pregnancy in, 333–334
 - contractions of, fetal cerebral hemodynamics and oxygenation during, 552–555
- dysfunction of, treatment for, pregnancy after,** 332–335
- prolapse of, in pregnancy,** 352–353, 358
- surgery on, pregnancy after,** 358

- Vaccination, 231–249**
 - advantages of, 232–233
 - for cytomegalovirus infections, 157–158, 241
 - for diarrheal diseases, 240–241
 - for enterovirus infections, 207–208
 - for group B streptococcal infections, 237
 - for *Haemophilus influenzae* type B infections, 238–240
 - for hepatitis B, 183–186, 234–235
 - for pneumococcal infections, 241
 - for polio, 207–208, 235–236
 - for respiratory syncytial virus infections, 238
 - for tetanus, 233–234
 - for tuberculosis, bacillus Calmette-Guerin in, 118–119, 236
 - for varicella, 196, 277
 - neonatal immunobiology and, 241–244
 - strategies for, 231–233
- Vacuum extraction, cranial injury from,** 846–847
- Vaginal fistulas, in labor and delivery,** 356
- Vaginosis, bacterial, diagnosis of,** 93
 - preterm birth and, 33–36
- Valvular heart disease, pregnancy in,** 471–472
- Vancamycin, in neonates,** 262–263
- Varicella zoster virus infections,** 193–196, 277–278
 - of central nervous system, 792–794
- Velo-cardio-facial syndrome, cardiac and neurologic manifestations of,** 817

- Venous sinuses, ultrasonography of, 683–685
in thrombosis, 681–682
- Ventilation, mechanical, intraventricular hemorrhage and, 593–594
- Ventricles, defects of, pregnancy in, 474
- Ventricular septal defect, pregnancy in, 470
- Ventriculomegaly, after intraventricular hemorrhage, brain injury in, 600–602
management of, 598–600
pathogenesis of, 596–598
prevention of, 598–600
causes of, 596–597
- Ventriculoperitoneal shunt, in hydrocephalus, 600
- Very-long-chain acyl-CoA dehydrogenase deficiency, encephalopathy in, 781–782
- Vidarabine, in herpes simplex virus infections, in neonates, 272–275
- Viral infections. *See also* specific infections.
central nervous system, seizures in, 757–758
treatment of, 267–283
- Vitamin A, teratogenicity of, 437–439
- Vitamin B₆ dependency on, seizures in, 761, 783
in pregnancy, 439
- Vitamin E, in hypoxic-ischemic brain injury prevention, 642
- Vitamin K, intraventricular hemorrhage and, 593
- Walker-Warburg syndrome, muscular dystrophy in, 834–835
- Warfarin, teratogenicity of, 476
- Watershed areas, of brain, vulnerability of, to hypoxic-ischemic injury, 634
- Weakness, in hypoxic-ischemic brain injury, 611
in neuromuscular disorders, 827
- Weight gain, in pregnancy, versus postpartum weight retention, 434–435
- Werdnig-Hoffman disease, 828–829
- Wheezing, in asthma, 409, 414
- White blood-cell transfusion, in neonatal sepsis, 217–218
- White matter, differentiation of, magnetic resonance imaging of, 699–702
- disorders of, in metabolic disorders, magnetic resonance imaging of, 709
- necrosis of, in periventricular hemorrhage, 568–569
- in periventricular leukomalacia, 574–575, 581–582
- Xanthine oxidase inhibitors, in hypoxic-ischemic brain injury prevention, 642–643
- Xenon-133 clearance method, for cerebral blood flow measurement, 538–539
- 47,XXX syndrome, pregnancy in, 463
- Zellweger syndrome, encephalopathy in, 783–784
- Zidovudine, in HIV infection, prophylactic, 167–170, 280, 795–796
- Zoster, 194, 277

